Endolymphatic Hydrops
Conditions
Keywords
CMV
Brief summary
The management of patients with a history of congenital CMV infection (whether symptomatic or asymptomatic at birth) is modeled on their usual management.
Detailed description
The management of patients with a history of congenital CMV infection (whether symptomatic or asymptomatic at birth) is modeled on their usual management. Patients benefit as part of the care: * A clinical cochleo-vestibular examination * Functional otoneurological explorations: audiogram, caloric tests, vHIT, otolithic evoked potentials * From an uninjected brain MRI Participation in this research entails the addition of an MRI sequence and an injection of contrast product (Gadovist®): \- 3D FLAIR MRI sequence dedicated to the exploration of the inner ear, lasting 6min30s, performed 4 hours after the initial injection of contrast product.
Interventions
Participation in this research entails the addition of an MRI sequence and an injection of contrast product (Gadovist®): \- 3D FLAIR MRI sequence dedicated to the exploration of the inner ear, lasting 6min30s, performed 4 hours after the initial injection of contrast product
Sponsors
Study design
Eligibility
Inclusion criteria
* Patient over 6 months old * With a history of confirmed congenital CMV infection * Suffering from symptomatic cochleo-vestibular dysfunction (average hearing threshold\> 20dB in at least one ear and / or abnormal functioning of one or more sectors at the vestibular level) * For adult patients, having received informed information about the study and having signed a consent to participate in the study * For minor patients written consent of the two holders of the exercise of parental authority * Affiliate or beneficiary of a social security scheme
Exclusion criteria
* Patient benefiting from a legal protection measure * Pregnant or breastfeeding woman * Contraindication to MRI (implanted electrical device, metallic foreign body, claustrophobia) * Patient with a proven allergy to gadolinium * Injection of gadolinium in the previous 7 days * Known impairment of renal function ((estimated GFR \<60 mL / min / 1.73 m²)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the prevalence of at least one endolymphatic hydrops in patients with a history of congenital CMV infection with symptomatic cochleovestibular dysfunction | 4 hours after the initial injection of gadolinium, at least for one of the two ears | Endolymphatic hydrops visualized with 3D FLAIR sequence in MRI |
Countries
France